• Clinical Info

Uses

Bleeding Due to Elevated Fibrinolytic Activity

Treatment of excessive bleeding resulting from systemic hyperfibrinolysis and urinary fibrinolysis. In life-threatening situations, fresh whole blood, fibrinogen infusions, and other emergency measures also may be required.

Used in systemic hyperfibrinolysis associated with surgical complications following heart surgery (with or without cardiac bypass procedures) and portacaval shunt; in carcinoma of the lung, prostate, cervix, or stomach; in abruptio placentae; and in hematologic disorders such as amegakaryocytic thrombocytopenia accompanying aplastic anemia (reduces the need for platelet transfusions).

Used in urinary fibrinolysis associated with complications of severe trauma, anoxia, and shock, and as manifested by surgical hematuria especially following prostatectomy and nephrectomy, or in nonsurgical hematuria accompanying polycystic or neoplastic disease of the GU tract.

Used in conjunction with heparin therapy in patients with acute promyelocytic leukemia†; initiate therapy when plasma α₂-antiplasmin (α₂-plasmin inhibitor) levels have decreased to <40% of normal levels.

Ocular Hemorrhage

Has been used effectively for the prevention of secondary ocular hemorrhage in patients with nonperforating traumatic hyphema†. Designated an orphan drug by FDA for topical treatment of traumatic hyphema.

Hereditary Hemorrhagic Telangiectasia

Has been used orally for the management of hereditary hemorrhagic telangiectasia†.

Dosage and Administration

Administration

Administer orally or by IV infusion.

Oral Administration

Administer orally if the patient is able to take oral medication.

IV Administration

For solution and drug compatibility information, see Compatibility under Stability.

Administer by IV infusion.

Avoid rapid IV administration; hypotension, bradycardia, and/or arrhythmia may result.

Dilution

For the initial infusion (loading dose), add 4–5 g of aminocaproic acid (16–20 mL of the injection) to 250 mL of diluent.

For maintenance infusions, add 1 g of aminocaproic acid (4 mL of the injection) to 50 mL of diluent to provide a final concentration of approximately 20 mg/mL.

Rate of Administration

Initial infusion (loading dose): Infuse 4–5 g over 1 hour in adults.

Maintenance infusion: Infuse 1 g per hour in adults.

Dosage

Pediatric Patients

Bleeding Due to Elevated Fibrinolytic Activity

Oral

100 mg/kg or 3 g/m² during the first hour, then 33.3 mg/kg per hour or 1 g/m² per hour (maximum 18 g/m² in 24 hours) has been used. Manufacturer states that safety and efficacy not established in pediatric patients.†

IV

Initial infusion (loading dose): 100 mg/kg or 3 g/m² over 1 hour has been used. Manufacturer states that safety and efficacy not established in pediatric patients.†

Maintenance infusion

Maintenance infusion: 33.3 mg/kg per hour or 1 g/m² per hour (maximum 18 g/m² in 24 hours) has been used. Manufacturer states that safety and efficacy not established in pediatric patients.†

Adults

Bleeding Due to Elevated Fibrinolytic Activity

Oral

5 g during the first hour, then 1–1.25 g per hour for about 8 hours or until bleeding has been controlled.

IV

Initial infusion (loading dose): 4–5 g over 1 hour.

Maintenance infusion: 1 g per hour for about 8 hours or until bleeding has been controlled.

Ocular Hemorrhage

Oral

100 mg/kg (up to 5 g) every 4 hours, up to a maximum daily dosage of 30 g, for 5 days has been used; lower daily dosages also may be effective.†

Hereditary Hemorrhagic Telangiectasia

Oral

1 or 1.5 g twice daily for 1–2 months, followed by 1–2 g daily.†

Prescribing Limits

Pediatric Patients

Bleeding Due to Elevated Fibrinolytic Activity

Oral or IV

Maximum 18 g/m² in 24 hours.†

Adults

Ocular Hemorrhage

Oral

Maximum 30 g daily.